We previously demonstrated in a randomized clinical trial (RCT) that methylphenidate
(MPH) treatment in boys, but not men, with attention-deficit/ hyperactivity disorder
(ADHD) alters dopamine function 1 week after RCT end. However, changes in dopamine
function did not correlate with clinical outcome. Here, we assess whether clinical
outcome at longitudinal follow-up is predicted by baseline dopamine function and whether
clinical outcome is modulated by medication.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Biological PsychiatryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2020 Published by Elsevier Inc.
